0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover191.45%IV-140.96%PremiumDec 20, 2024Expiry Date5.85Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9475Delta0.0630Gamma0.70Leverage Ratio-0.0039Theta-0.0031Rho-0.66Eff Leverage0.0011Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet